




# Research and Industry

Ventipet is a revolutionary diagnosis tool for the characterization of pulmonary ventilation. This marker consists of an innocuous radiofluorinated gas, that allows to sharply visualize the gaseous content in the lungs throughout the whole respiratory process.

**According to the World Health Organization, hundreds of millions of people of all ages suffer from preventable chronic respiratory diseases and respiratory allergies worldwide. The burden of preventable respiratory conditions has major adverse effects on the quality of life of the affected individuals.\***

Ventipet is the only pulmonary gaseous ventilation marker compatible with positron emission tomography (PET). Due to its superior image quality, spatiotemporal resolution, and improved accuracy, PET is the nuclear imaging technique of choice with an exponential growth in the last years.


### **Number of PET scanner per million inhabitants. Distribution by country.**



Global landscape of PET scanners. Ventipet is the first-of-its-kind PET-compatible pulmonary gaseous radiotracer.

Ventipet is a gaseous radiotracer presented in single-dose, ready-to-use, airtight containers, produced in radiopharmaceutical facilities that supply the product to healthcare centers. The production process of Ventipet is compatible with any type of medical cyclotron and with the production of other radiotracers, and can be manufactured during production downtimes as short irradiation times suffice to produce multiple doses. Ventipet half-life makes it compatible with current delivery schemes in the already established global distribution networks for the most employed PET radiotracers in the clinical scenario.


\*<https://www.who.int/gard/publications/Overview.pdf?ua=1#:~:text=Hundreds%20of%20millions%20of%20people,income%20countries%20or%20deprived%20populations.>




Ready-to-use Ventipet doses are delivered to healthcare centers equipped with PET scanners and are administered to the patients through inhalation, without the need of previous training and through natural respiration.

The administration system consists of a disposable single-use kit. The management of the residuals and waste only requires the storage of the materials for 24 hours, until complete radioactive decay. Thanks to Ventipet innovative composition and PET scans accuracy, the required time and the dose to perform the diagnostic tests are considerably lower compared to other radiotracers. In consequence, the exposition of technical personnel and patients to radiation is dramatically reduced. The evacuation of the gas from the lungs once the procedure is over, results in a low residence time and guarantees an absolute control over the patient's dosimetry. Ventipet requires barely no additional investment from the clinical centers equiped with PET scanners, and provides benefits for the medical personnel and patients.

### RAPID CLEARANCE



### ACCURATE IMAGING



PET image at activity peak

The simplicity and convenience of the administration method makes Ventipet eligible for a wide range of patients, even those with severely compromised pulmonary ventilation. In this way, Ventipet administration system combined with the efficiency of PET, allows to obtain a faithful representation of lung ventilation through the respiratory cycle.

#### Key Research and Industry facts

- Ventipet is a gas. Thus, it does not accumulate in the central airways and faithfully represents pulmonary ventilation.
- Imaging studies require very low concentrations of Ventipet due to the high sensitivity of PET.
- Ventipet is poorly soluble in water, minimizing translocation to the bloodstream and remote organs.
- Contrary to other commercially available ventilation markers, Ventipet can be produced in specialised centres all over the world and distributed to end users in a single- or multi-dose fashion.

Ventipet has been envisaged in the context of chronic lung diseases (COPD, asthma), lung cancer, Pulmonary Disease (PD) and COVID-19 or other infections that affect the lungs. Together, these diseases affect, worldwide, more than 800 million patients who can benefit directly from the implementation of ventilation in healthcare centers.

Altogether, Ventipet proprietary technology is a powerful and profitable innovative tool to build the future of lung ventilation imaging. Join us in this science inspired endeavour towards an impactful step in the healthcare sector.



Research, Development  
and Innovation



Versatile production in  
radiopharmaceutical  
facilities worldwide



Airtight ready-to-use  
single-dose containers



On-demand delivery to  
healthcare centers



Patient-friendly administration



Improved lung ventilation  
clinical assessment